Full Text View
Tabular View
No Study Results Posted
Related Studies
Proof-of-Concept Safety Study of CPP-109(Vigabatrin) for Treatment Refractory Tourette's Disorder
This study is currently recruiting participants.
Verified January 2013 by Mount Sinai School of Medicine
Study NCT01585207   Information provided by Mount Sinai School of Medicine

First Received on April 24, 2012.   Last Updated on January 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tourette's Disorder
Additional conditions recognized in this trial
Tourette Syndrome
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tic Disorders
Interventions listed in this trial
vigabatrin
More general drug interventions related to this trial
Anticonvulsants
Central Nervous System Agents
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Barbara J. Coffey


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services